Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease
| Autor: | Evangelos, Tsipotis, Sarah, Frey, Caoilfhionn, Connolly, William A, Werbel, Reezwana, Chowdhury, Sharon, Dudley-Brown, Joanna M, Melia, Alyssa M, Parian, Brindusa, Truta, Huimin, Yu, Florin M, Selaru, Dorry L, Segev, Mark, Lazarev |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | American Journal of Gastroenterology. 117:798-801 |
| ISSN: | 1572-0241 0002-9270 |
| DOI: | 10.14309/ajg.0000000000001668 |
| Popis: | The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.Larger longitudinal studies are required to define the response in IBD population and its clinical impact. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|